Farnesoid X receptor modulators (2011 - 2014): a patent review.
作者： Valentina Sepe , Eleonora Distrutti , Stefano Fiorucci , Angela Zampella
DOI: 10.1517/13543776.2015.1045413
关键词:
摘要: Introduction: Farnesoid-X-receptor (FXR) is the receptor for primary bile acids expressed in enterohepatic tissues where it regulates acid uptake, metabolism and disposal. For its role as a sensor, FXR has been thought to be an important target treatment of cholestatic disorders, family diseases which endogenous accumulate body. Cholestasis might occur consequence inborn metabolic errors three major intra-hepatic cholestasis pregnancy, biliary cirrhosis (PBC) sclerosing cholangitis account vast majority clinical occurring adulthood. In addition, agonists are gaining attention potential regulators lipid glucose therefore new therapeutical approaches fatty liver disease, type 2 diabetes obesity.Areas covered: New chemical entities modulators their vitro vivo efficacy reviewed with particular focus on patents a...
informahealthcare.com
core.ac.uk 参考文章(54)
Jyrki J. Eloranta, Peter J. Meier, Gerd A. Kullak‐Ublick, Coordinate Transcriptional Regulation of Transport and Metabolism Methods in Enzymology. ,vol. 400, pp. 511- 530 ,(2005) , 10.1016/S0076-6879(05)00028-5
David C. Tully, Daniel Mutnick, Phillip B. Alper, Agnes Vidal, Compositions and methods for modulating farnesoid x receptors ,(2011)
Claus Kremoser, Ulrich Deuschle, Farnesoid x receptor agonists for cancer treatment and prevention ,(2012)
Michael R. Jirousek, Allison Wensley, Jill C. Milne, Amal Ting, Chi B. Vu, Fatty acid conjugates of statin and fxr agonists; compositions and method of uses ,(2013)
Haibo Wang, Jasmine Chen, Kevin Hollister, Lawrence C Sowers, Barry M Forman, Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Molecular Cell. ,vol. 3, pp. 543- 553 ,(1999) , 10.1016/S1097-2765(00)80348-2
Li-Zhi Mi, Srikripa Devarakonda, Joel M. Harp, Qing Han, Roberto Pellicciari, Timothy M. Willson, Sepideh Khorasanizadeh, Fraydoon Rastinejad, Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR Molecular Cell. ,vol. 11, pp. 1093- 1100 ,(2003) , 10.1016/S1097-2765(03)00112-6
Peter Fickert, Andrea Fuchsbichler, Tarek Moustafa, Martin Wagner, Gernot Zollner, Emina Halilbasic, Ulrike Stöger, Marco Arrese, Margarita Pizarro, Nancy Solís, Gonzalo Carrasco, Alessandra Caligiuri, Martina Sombetzki, Emil Reisinger, Oleksiy Tsybrovskyy, Kurt Zatloukal, Helmut Denk, Hartmut Jaeschke, Massimo Pinzani, Michael Trauner, Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts American Journal of Pathology. ,vol. 175, pp. 2392- 2405 ,(2009) , 10.2353/AJPATH.2009.090114
Francesco Saverio Di Leva, Carmen Festa, Claudio D’Amore, Simona De Marino, Barbara Renga, Maria Valeria D’Auria, Ettore Novellino, Vittorio Limongelli, Angela Zampella, Stefano Fiorucci, Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands Journal of Medicinal Chemistry. ,vol. 56, pp. 4701- 4717 ,(2013) , 10.1021/JM400419E
Barry M Forman, Elizabeth Goode, Jasmine Chen, Anthony E Oro, David J Bradley, Thomas Perlmann, Daniel J Noonan, Leo T Burka, Trevor McMorris, William W Lamph, Ronald M Evans, Cary Weinberger, IDENTIFICATION OF A NUCLEAR RECEPTOR THAT IS ACTIVATED BY FARNESOL METABOLITES Cell. ,vol. 81, pp. 687- 693 ,(1995) , 10.1016/0092-8674(95)90530-8
A. Mason, V. Luketic, K. Lindor, G. Hirschfield, S. Gordon, M. Mayo, K. Kowdley, A. Parés, M. Trauner, E. Castelloe, C. Sciacca, T.B. Jones, O. Böhm, D. Shapiro, 2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID Journal of Hepatology. ,vol. 52, ,(2010) , 10.1016/S0168-8278(10)60004-9